Twist Bioscience Corp. Hits New 52-Week High at $65.06

Twist Bioscience Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 65.06 on April 21, 2026. This achievement marks a notable increase from its 52-week low of USD 23.50, reflecting a robust performance over the past year. The company has demonstrated a 1-year performance of 25.19%, although this is below the S&P 500's performance of 36.95% during the same period. With a market capitalization of USD 2,760 million, Twist Bioscience operates in a competitive industry where innovation and growth are critical. Despite being a loss-making entity, the company’s financial metrics reveal a debt-to-equity ratio of -0.41 and a return on equity of -16.79%. The price-to-book ratio stands at 6.05, indicating how the market values the company's equity relative to its book value. As Twist Bioscience continues to navigate the dynamic landscape of biotechnology, its recent price achievement underscores its current market position and performance trends.